Good morning!
There’s a comment below, “Should we consider shorting MKS?”
My answer (subject to the usual disclaimer: no advice) is a resounding yes!
It has many of the features of an attractive short:
legacy, disrupted (not disruptive) business modelshrinking revenuesnot much evidence of any economic/competitive moatlow margincapital intensivefinancially geared (financial net debt £1.6 billion, plus lease liabilities)Bar skimming the headlines, I haven’t studied its results in detail today. But if I was looking for another short candidate, this stock would be my immediate focus. For now, my shorting energies are dedicated elsewhere.
Competition amp; Markets AuthorityAn update on a minor matter.On September 17th, I wrote to the CMA and asked them to put more information in their RNS headlines, to help speed up my work and the work of everyone else who checks the RNS feed every day.I was informed that the team responsible for scheduling RNS updates had been forwarded my message.It turns out that they implemented my suggestion from September 19th:Thank you, CMA!So which small-caps am I going to look at today?Provisional list:Park (LON:PARK)Innovaderma (LON:IDP)
Disclaimer: Please note all prices are for information only, they should not be relied upon for accuracy or trading. All prices quotes are based on CFD prices and are similar though not always identical to real exchange prices. STOCKTRKR or anybody connected with STOCKTRKR will not accept any liability for loss or damage arising from use of any information/commentary/charts or articles which is provided 'as is' for educational purposes only, nothing contained on this website should be considered as investment advice - please seek proper investment advice from registered financial broker or institution if you wish to trade on global markets and ensure you are familiar with the risks.
